Current and emerging strategies in the management of Crohn's disease

Charles Randall, John Vizuete, Gregg Wendorf, Balaji Ayyar, Gregory Constantine

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Diarrhoea is a common manifestation of Crohn's disease (CD). We advocate an evidence-based approach to treat the underlying disease and reduce symptoms. This article reviews disease grading systems, current concepts in medical therapy, and other treatments that may become available in the future. While some drug classes (e.g. salicylates, immunomodulators) have been studied for many decades, newer approaches including anti-TNF monoclonal antibodies (biologics), and gut selective agents are changing the paradigm we use to treat this debilitating condition.

Original languageEnglish (US)
Pages (from-to)601-610
Number of pages10
JournalBest Practice and Research: Clinical Gastroenterology
Volume26
Issue number5
DOIs
StatePublished - Oct 2012
Externally publishedYes

Fingerprint

Crohn Disease
Salicylates
Immunologic Factors
Biological Products
Diarrhea
Monoclonal Antibodies
Pharmaceutical Preparations
Therapeutics

Keywords

  • Crohn's disease
  • Diarrhoea
  • IBD

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Current and emerging strategies in the management of Crohn's disease. / Randall, Charles; Vizuete, John; Wendorf, Gregg; Ayyar, Balaji; Constantine, Gregory.

In: Best Practice and Research: Clinical Gastroenterology, Vol. 26, No. 5, 10.2012, p. 601-610.

Research output: Contribution to journalReview article

Randall, Charles ; Vizuete, John ; Wendorf, Gregg ; Ayyar, Balaji ; Constantine, Gregory. / Current and emerging strategies in the management of Crohn's disease. In: Best Practice and Research: Clinical Gastroenterology. 2012 ; Vol. 26, No. 5. pp. 601-610.
@article{812b238e784546609f6be0eb09373dcd,
title = "Current and emerging strategies in the management of Crohn's disease",
abstract = "Diarrhoea is a common manifestation of Crohn's disease (CD). We advocate an evidence-based approach to treat the underlying disease and reduce symptoms. This article reviews disease grading systems, current concepts in medical therapy, and other treatments that may become available in the future. While some drug classes (e.g. salicylates, immunomodulators) have been studied for many decades, newer approaches including anti-TNF monoclonal antibodies (biologics), and gut selective agents are changing the paradigm we use to treat this debilitating condition.",
keywords = "Crohn's disease, Diarrhoea, IBD",
author = "Charles Randall and John Vizuete and Gregg Wendorf and Balaji Ayyar and Gregory Constantine",
year = "2012",
month = "10",
doi = "10.1016/j.bpg.2012.11.006",
language = "English (US)",
volume = "26",
pages = "601--610",
journal = "Bailliere's Best Practice and Research in Clinical Gastroenterology",
issn = "1521-6918",
publisher = "Bailliere Tindall Ltd",
number = "5",

}

TY - JOUR

T1 - Current and emerging strategies in the management of Crohn's disease

AU - Randall, Charles

AU - Vizuete, John

AU - Wendorf, Gregg

AU - Ayyar, Balaji

AU - Constantine, Gregory

PY - 2012/10

Y1 - 2012/10

N2 - Diarrhoea is a common manifestation of Crohn's disease (CD). We advocate an evidence-based approach to treat the underlying disease and reduce symptoms. This article reviews disease grading systems, current concepts in medical therapy, and other treatments that may become available in the future. While some drug classes (e.g. salicylates, immunomodulators) have been studied for many decades, newer approaches including anti-TNF monoclonal antibodies (biologics), and gut selective agents are changing the paradigm we use to treat this debilitating condition.

AB - Diarrhoea is a common manifestation of Crohn's disease (CD). We advocate an evidence-based approach to treat the underlying disease and reduce symptoms. This article reviews disease grading systems, current concepts in medical therapy, and other treatments that may become available in the future. While some drug classes (e.g. salicylates, immunomodulators) have been studied for many decades, newer approaches including anti-TNF monoclonal antibodies (biologics), and gut selective agents are changing the paradigm we use to treat this debilitating condition.

KW - Crohn's disease

KW - Diarrhoea

KW - IBD

UR - http://www.scopus.com/inward/record.url?scp=84873341789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873341789&partnerID=8YFLogxK

U2 - 10.1016/j.bpg.2012.11.006

DO - 10.1016/j.bpg.2012.11.006

M3 - Review article

C2 - 23384805

AN - SCOPUS:84873341789

VL - 26

SP - 601

EP - 610

JO - Bailliere's Best Practice and Research in Clinical Gastroenterology

JF - Bailliere's Best Practice and Research in Clinical Gastroenterology

SN - 1521-6918

IS - 5

ER -